TLSI ▲ +18.5% - TriSalus Life Sciences, Inc. $TLSI TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization TriSalus Life Sciences shares rose 18.5% following the company's announcement that the FDA has cleared TriNav® Advance, an addition to its pressure-enabled drug delivery portfolio designed for liver embolization procedures. The clearance expands TriSalus's treatment options in what the company describes as its comprehensive PEDD technology platform, which likely contributed to investor optimism about the company's commercial prospects. 22-SEP-2026 04:15 PM ET